53
Participants
Start Date
January 10, 2022
Primary Completion Date
January 1, 2026
Study Completion Date
January 1, 2027
Isatuximab (for run-in portion)
10 mg/kg IV on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles.
Isatuximab (for expansion)
10 mg/kg IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles.
Pomalidomide
4 mg PO days 1-21 of each cycle.
Elotuzumab
10 mg/kg on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles.
Dexamethasone
40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
RECRUITING
The University of Alabama at Birmingham, Birmingham
RECRUITING
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Medical College of Wisconsin
OTHER